Related references
Note: Only part of the references are listed.National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents
Maria Lucia Gomes Ferraz et al.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2022)
Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
Jui-Ting Hsu et al.
MEDICINA-LITHUANIA (2022)
Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection
Akio Miyasaka et al.
HEALTH SCIENCE REPORTS (2022)
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naive adults with chronic hepatitis C virus genotypes 1-6 in Brazil
Mario Peribanez-Gonzaleza et al.
ANNALS OF HEPATOLOGY (2021)
Therapy of chronic hepatitis C in people who inject drugs: focus on adherence
Sona Frankova et al.
HARM REDUCTION JOURNAL (2021)
An update on direct antiviral agents for the treatment of hepatitis C
Carol Stanciu et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
Nese Demirturk et al.
TURKISH JOURNAL OF GASTROENTEROLOGY (2021)
Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness
Nahed A. Makhlouf et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2021)
Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis
Yukihisa Yuri et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease A real-life experience
Sherief Abd-Elsalam et al.
MEDICINE (2020)
Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents
Brianna L. Norton et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
Amr Elsayed et al.
BMJ OPEN GASTROENTEROLOGY (2020)
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
Gamal Shiha et al.
GUT (2019)
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
Peter Ferenci et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Ombitasvir/paritaprevir/ritonavir plus dasabuvir plus /- ribavirin in real world hepatitis C patients
Nicole Loo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Ombitasvir/paritaprevir/ritonavir plus dasabuvir plus ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)
Vasily Isakov et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Paul Y. Kwo et al.
JOURNAL OF HEPATOLOGY (2017)
Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study
N. Tozun et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease
Yi-Chun Chen et al.
KIDNEY INTERNATIONAL (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis
Ross J. Harris et al.
EUROPEAN JOURNAL OF PUBLIC HEALTH (2012)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients
F Fabrizi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)